Pfizer signs licence agreement with Chai for AI drug discovery
According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model.
Drug Development
Biogen’s salanersen gains FDA breakthrough therapy designation for SMA
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
AbbVie receives EC approval for Aquipta to treat migraine
Roche’s giredestrant secures FDA priority review for breast cancer
BMS secures FDA acceptance for Camzyos sNDA
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
